DNAJC5 and malaria: The RTS, S/AS01 (MosquirixTM), the first-ever malaria vaccine based on P. falciparum circumsporozoite protein (CSP), suffers low efficacy [2] with waning anti-CSP antibodies post-vaccination [3].